{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:03:31Z","timestamp":1762625011297,"version":"3.37.3"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81871858","82172550"],"award-info":[{"award-number":["No. 81871858","82172550"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10557-023-07463-y","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:36:35Z","timestamp":1684161395000},"page":"999-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Regulatory T Cells in Pathological Cardiac Hypertrophy: Mechanisms and Therapeutic Potential"],"prefix":"10.1007","volume":"38","author":[{"given":"Leiling","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huali","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-0800","authenticated-orcid":false,"given":"Danyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"7463_CR1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","volume":"97","author":"I Shimizu","year":"2016","unstructured":"Shimizu I. Minamino T Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016;97:245\u201362.","journal-title":"J Mol Cell Cardiol"},{"key":"7463_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1161\/CIRCULATIONAHA.120.051094","volume":"144","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Da Q, Cao S, et al. HINT1 (histidine triad nucleotide-binding protein 1) attenuates cardiac hypertrophy via suppressing HOXA5 (Homeobox A5) expression. Circulation. 2021;144:638\u201354.","journal-title":"Circulation"},{"key":"7463_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ. Braunwald E Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749\u201370.","journal-title":"Circ Res"},{"key":"7463_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura M. Sadoshima J Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15:387\u2013407.","journal-title":"Nat Rev Cardiol"},{"key":"7463_CR5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1073\/pnas.0813013106","volume":"106","author":"J Backs","year":"2009","unstructured":"Backs J, Backs T, Neef S, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009;106:2342\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7463_CR6","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1161\/CIRCULATIONAHA.116.022495","volume":"134","author":"CF Lee","year":"2016","unstructured":"Lee CF, Chavez JD, Garcia-Menendez L, et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation. 2016;134:883\u201394.","journal-title":"Circulation"},{"key":"7463_CR7","doi-asserted-by":"crossref","unstructured":"Horton JL, Martin OJ, Lai L, et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight. 2016;2(1):e84897.","DOI":"10.1172\/jci.insight.84897"},{"key":"7463_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/CIRCULATIONAHA.114.008788","volume":"131","author":"RA Frieler","year":"2015","unstructured":"Frieler RA. Mortensen RM Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131:1019\u201330.","journal-title":"Circulation"},{"key":"7463_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1161\/CIRCULATIONAHA.117.030811","volume":"138","author":"L Zhou","year":"2018","unstructured":"Zhou L, Miao K, Yin B, et al. Cardioprotective role of myeloid-derived suppressor cells in heart failure. Circulation. 2018;138:181\u201397.","journal-title":"Circulation"},{"key":"7463_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","volume":"74","author":"I Raphael","year":"2015","unstructured":"Raphael I, Nalawade S, Eagar TN, et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74:5\u201317.","journal-title":"Cytokine"},{"key":"7463_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/intimm\/dxw006","volume":"28","author":"K Hirahara","year":"2016","unstructured":"Hirahara K. Nakayama T CD4+ T-cell subsets in inflammatory diseases: beyond the Th1\/Th2 paradigm. Int Immunol. 2016;28:163\u201371.","journal-title":"Int Immunol"},{"key":"7463_CR12","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/eji.202049123","volume":"51","author":"V Saxena","year":"2021","unstructured":"Saxena V, Lakhan R, Iyyathurai J, et al. Mechanisms of exTreg induction. Eur J Immunol. 2021;51:1956\u201367.","journal-title":"Eur J Immunol"},{"key":"7463_CR13","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1007\/s11033-021-06483-x","volume":"48","author":"R Kuan","year":"2021","unstructured":"Kuan R, Agrawal DK. Thankam FG Treg cells in atherosclerosis. Mol Biol Rep. 2021;48:4897\u2013910.","journal-title":"Mol Biol Rep"},{"key":"7463_CR14","doi-asserted-by":"crossref","unstructured":"Shackleton EG, Ali HY, Khan M, et al. Novel combinatorial approaches to tackle the immunosuppressive microenvironment of prostate cancer. Cancers (Basel). 2021;13(5):1145.","DOI":"10.3390\/cancers13051145"},{"key":"7463_CR15","doi-asserted-by":"crossref","unstructured":"Gouirand V, Habrylo I, Rosenblum MD. Regulatory T cells and inflammatory mediators in autoimmune disease. J Invest Dermatol.\u00a02021;142(3 Pt B):774\u2013780.","DOI":"10.1016\/j.jid.2021.05.010"},{"key":"7463_CR16","doi-asserted-by":"publisher","first-page":"635767","DOI":"10.3389\/fimmu.2021.635767","volume":"12","author":"V Volfson-Sedletsky","year":"2021","unstructured":"Volfson-Sedletsky V, Jones AT, Hernandez-Escalante J, et al. Emerging therapeutic strategies to restore regulatory T cell control of islet autoimmunity in type 1 diabetes. Front Immunol. 2021;12:635767.","journal-title":"Front Immunol"},{"key":"7463_CR17","doi-asserted-by":"publisher","first-page":"5590217","DOI":"10.1155\/2021\/5590217","volume":"2021","author":"J Li","year":"2021","unstructured":"Li J, Sha J, Sun L, et al. Contribution of regulatory T cell methylation modifications to the pathogenesis of allergic airway diseases. J Immunol Res. 2021;2021:5590217.","journal-title":"J Immunol Res"},{"key":"7463_CR18","doi-asserted-by":"crossref","unstructured":"Demosthenous C, Sakellari I, Douka V, et al. The role of myeloid-derived suppressor cells (MDSCs) in graft-versus-host disease (GVHD). J Clin Med.\u00a02021;10(10):2050.","DOI":"10.3390\/jcm10102050"},{"key":"7463_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00125-021-05595-0","volume":"65","author":"J Boldison","year":"2022","unstructured":"Boldison J, Long AE, Aitken RJ, et al. Activated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes. Diabetologia. 2022;65:343\u201355.","journal-title":"Diabetologia"},{"key":"7463_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaut.2011.06.002","volume":"37","author":"CR Li","year":"2011","unstructured":"Li CR, Deiro MF, Godebu E, et al. IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-\u03b27-dependent localization. J Autoimmun. 2011;37:217\u201327.","journal-title":"J Autoimmun"},{"key":"7463_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.2337\/db20-0896","volume":"70","author":"V Mhanna","year":"2021","unstructured":"Mhanna V, Fourcade G, Barennes P, et al. Impaired activated\/memory regulatory T cell clonal expansion instigates diabetes in NOD mice. Diabetes. 2021;70:976\u201385.","journal-title":"Diabetes"},{"key":"7463_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10:1000\u20137.","journal-title":"Nat Immunol"},{"key":"7463_CR23","doi-asserted-by":"crossref","unstructured":"Lee S, Bartlett B, Dwivedi G. Adaptive immune responses in human atherosclerosis. Int J Mol Sci.\u00a02020;21(23):9322.","DOI":"10.3390\/ijms21239322"},{"key":"7463_CR24","doi-asserted-by":"publisher","first-page":"8821029","DOI":"10.1155\/2020\/8821029","volume":"2020","author":"X He","year":"2020","unstructured":"He X, Liang B. Gu N Th17\/Treg imbalance and atherosclerosis. Dis Markers. 2020;2020:8821029.","journal-title":"Dis Markers"},{"key":"7463_CR25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/aps.2017.140","volume":"39","author":"HX Ou","year":"2018","unstructured":"Ou HX, Guo BB, Liu Q, et al. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharmacol Sin. 2018;39:1249\u201358.","journal-title":"Acta Pharmacol Sin"},{"key":"7463_CR26","doi-asserted-by":"publisher","first-page":"e003688","DOI":"10.1161\/CIRCHEARTFAILURE.116.003688","volume":"10","author":"SS Bansal","year":"2017","unstructured":"Bansal SS, Ismahil MA, Goel M, et al. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ Heart Fail. 2017;10:e003688.","journal-title":"Circ Heart Fail"},{"key":"7463_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.121.055888","volume":"145","author":"G Feng","year":"2022","unstructured":"Feng G, Bajpai G, Ma P, et al. CCL17 aggravates myocardial injury by suppressing recruitment of regulatory T cells. Circulation. 2022;145:765\u201382.","journal-title":"Circulation"},{"key":"7463_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1161\/CIRCULATIONAHA.118.036065","volume":"139","author":"SS Bansal","year":"2019","unstructured":"Bansal SS, Ismahil MA, Goel M, et al. Dysfunctional and proinflammatory regulatory T-lymphocytes are essential for adverse cardiac remodeling in ischemic cardiomyopathy. Circulation. 2019;139:206\u201321.","journal-title":"Circulation"},{"key":"7463_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/CIRCRESAHA.115.303895","volume":"115","author":"J Weirather","year":"2014","unstructured":"Weirather J, Hofmann UD, Beyersdorf N, et al. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte\/macrophage differentiation. Circ Res. 2014;115:55\u201367.","journal-title":"Circ Res"},{"key":"7463_CR30","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1161\/CIRCULATIONAHA.108.832782","volume":"119","author":"H Kvakan","year":"2009","unstructured":"Kvakan H, Kleinewietfeld M, Qadri F, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 2009;119:2904\u201312.","journal-title":"Circulation"},{"key":"7463_CR31","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","volume":"4","author":"S Oparil","year":"2018","unstructured":"Oparil S, Acelajado MC, Bakris GL, et al. Hypertension Nat Rev Dis Primers. 2018;4:18014.","journal-title":"Hypertension Nat Rev Dis Primers"},{"key":"7463_CR32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","volume":"275","author":"D Levy","year":"1996","unstructured":"Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557\u201362.","journal-title":"JAMA"},{"key":"7463_CR33","doi-asserted-by":"crossref","unstructured":"Brenes-Castro D, Castillo EC, V\u00e1zquez-Garza E, et al. Temporal frame of immune cell infiltration during heart failure establishment: lessons from animal models. Int J Mol Sci.\u00a02018;19(12):3719.","DOI":"10.3390\/ijms19123719"},{"key":"7463_CR34","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1097\/HJH.0000000000002456","volume":"38","author":"A Rai","year":"2020","unstructured":"Rai A, Narisawa M, Li P, et al. Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications. J Hypertens. 2020;38:1878\u201389.","journal-title":"J Hypertens"},{"key":"7463_CR35","doi-asserted-by":"publisher","first-page":"H938","DOI":"10.1152\/ajpheart.00707.2009","volume":"298","author":"EC Viel","year":"2010","unstructured":"Viel EC, Lemari\u00e9 CA, Benkirane K, et al. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010;298:H938-944.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7463_CR36","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1161\/CIRCULATIONAHA.119.045344","volume":"142","author":"C Cui","year":"2020","unstructured":"Cui C, Fan J, Zeng Q, et al. CD4(+) T-cell endogenous cystathionine \u03b3 lyase-hydrogen sulfide attenuates hypertension by sulfhydrating liver kinase B1 to promote T regulatory cell differentiation and proliferation. Circulation. 2020;142:1752\u201369.","journal-title":"Circulation"},{"key":"7463_CR37","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1097\/HJH.0b013e328349c62d","volume":"29","author":"P Kanellakis","year":"2011","unstructured":"Kanellakis P, Dinh TN, Agrotis A, et al. CD4+CD25+Foxp3+ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J Hypertens. 2011;29:1820\u20138.","journal-title":"J Hypertens"},{"key":"7463_CR38","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1161\/HYPERTENSIONAHA.110.162941","volume":"57","author":"T Barhoumi","year":"2011","unstructured":"Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469\u201376.","journal-title":"Hypertension"},{"key":"7463_CR39","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1128\/MCB.00518-15","volume":"35","author":"S Fabbiano","year":"2015","unstructured":"Fabbiano S, Menacho-M\u00e1rquez M, Robles-Valero J, et al. Immunosuppression-independent role of regulatory T cells against hypertension-driven renal dysfunctions. Mol Cell Biol. 2015;35:3528\u201346.","journal-title":"Mol Cell Biol"},{"key":"7463_CR40","doi-asserted-by":"publisher","first-page":"H1287","DOI":"10.1152\/ajpheart.00096.2016","volume":"311","author":"GE Gonz\u00e1lez","year":"2016","unstructured":"Gonz\u00e1lez GE, Rhaleb NE, D\u2019Ambrosio MA, et al. Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2016;311:H1287-h1296.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7463_CR41","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.jacc.2012.02.093","volume":"60","author":"MR Dweck","year":"2012","unstructured":"Dweck MR, Boon NA. Newby DE Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60:1854\u201363.","journal-title":"J Am Coll Cardiol"},{"key":"7463_CR42","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jcmg.2016.10.007","volume":"10","author":"CWL Chin","year":"2017","unstructured":"Chin CWL, Everett RJ, Kwiecinski J, et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc Imaging. 2017;10:1320\u201333.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7463_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.051052","volume":"125","author":"MR Dweck","year":"2012","unstructured":"Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 2012;125:76\u201386.","journal-title":"Circulation"},{"key":"7463_CR44","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/CH-190594","volume":"73","author":"O Gilicze","year":"2019","unstructured":"Gilicze O, Simon D, Farkas N, et al. Characterization of lymphocyte subpopulations and cardiovascular markers in pericardial fluid of cardiac surgery patients. Clin Hemorheol Microcirc. 2019;73:579\u201390.","journal-title":"Clin Hemorheol Microcirc"},{"key":"7463_CR45","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ehf2.12837","volume":"7","author":"J Hoffmann","year":"2020","unstructured":"Hoffmann J, Mas-Peiro S, Berkowitsch A, et al. Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation. ESC Heart Fail. 2020;7:2597\u2013610.","journal-title":"ESC Heart Fail"},{"key":"7463_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/imr.12172","volume":"259","author":"J Barbi","year":"2014","unstructured":"Barbi J, Pardoll D. Pan F Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014;259:115\u201339.","journal-title":"Immunol Rev"},{"key":"7463_CR47","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/eji.201242909","volume":"43","author":"LA Smyth","year":"2013","unstructured":"Smyth LA, Ratnasothy K, Tsang JY, et al. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function. Eur J Immunol. 2013;43:2430\u201340.","journal-title":"Eur J Immunol"},{"key":"7463_CR48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fgene.2019.00604","volume":"10","author":"I Kudryavtsev","year":"2019","unstructured":"Kudryavtsev I, Serebriakova M, Zhiduleva E, et al. CD73 rather than CD39 is mainly involved in controlling purinergic signaling in calcified aortic valve disease. Front Genet. 2019;10:604.","journal-title":"Front Genet"},{"key":"7463_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijcard.2016.05.039","volume":"218","author":"S Shimoni","year":"2016","unstructured":"Shimoni S, Bar I, Meledin V, et al. Circulating regulatory T cells in patients with aortic valve stenosis: association with disease progression and aortic valve intervention. Int J Cardiol. 2016;218:181\u20137.","journal-title":"Int J Cardiol"},{"key":"7463_CR50","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/eurheartj\/ehv592","volume":"37","author":"F Montecucco","year":"2016","unstructured":"Montecucco F, Carbone F. Schindler TH Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments. Eur Heart J. 2016;37:1268\u201383.","journal-title":"Eur Heart J"},{"key":"7463_CR51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255\u201365.","journal-title":"Nat Rev Cardiol"},{"key":"7463_CR52","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1161\/ATVBAHA.112.251579","volume":"32","author":"M Wigren","year":"2012","unstructured":"Wigren M, Bj\u00f6rkbacka H, Andersson L, et al. Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler Thromb Vasc Biol. 2012;32:2000\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7463_CR53","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jacc.2015.01.027","volume":"65","author":"D Flego","year":"2015","unstructured":"Flego D, Severino A, Trotta F, et al. Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2015;65:1175\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"7463_CR54","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/eurheartj\/eht543","volume":"36","author":"R Klingenberg","year":"2015","unstructured":"Klingenberg R, Brokopp CE, Griv\u00e8s A, et al. Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. Eur Heart J. 2015;36:1041\u20138.","journal-title":"Eur Heart J"},{"key":"7463_CR55","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1161\/HYPERTENSIONAHA.119.12852","volume":"74","author":"L Zhu","year":"2019","unstructured":"Zhu L, Jia L, Liu Z, et al. Elevated methylation of FOXP3 (Forkhead Box P3)-TSDR (regulatory T-cell-specific demethylated region) is associated with increased risk for adverse outcomes in patients with acute coronary syndrome. Hypertension. 2019;74:581\u20139.","journal-title":"Hypertension"},{"key":"7463_CR56","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00395-011-0232-6","volume":"107","author":"TT Tang","year":"2012","unstructured":"Tang TT, Yuan J, Zhu ZF, et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol. 2012;107:232.","journal-title":"Basic Res Cardiol"},{"key":"7463_CR57","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1536\/ihj.52.382","volume":"52","author":"K Matsumoto","year":"2011","unstructured":"Matsumoto K, Ogawa M, Suzuki J, et al. Regulatory T lymphocytes attenuate myocardial infarction-induced ventricular remodeling in mice. Int Heart J. 2011;52:382\u20137.","journal-title":"Int Heart J"},{"key":"7463_CR58","doi-asserted-by":"publisher","first-page":"H1233","DOI":"10.1152\/ajpheart.00328.2014","volume":"307","author":"A Saxena","year":"2014","unstructured":"Saxena A, Dobaczewski M, Rai V, et al. Regulatory T cells are recruited in the infarcted mouse myocardium and may modulate fibroblast phenotype and function. Am J Physiol Heart Circ Physiol. 2014;307:H1233-1242.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7463_CR59","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1172\/JCI123859","volume":"129","author":"M Rieckmann","year":"2019","unstructured":"Rieckmann M, Delgobo M, Gaal C, et al. Myocardial infarction triggers cardioprotective antigen-specific T helper cell responses. J Clin Invest. 2019;129:4922\u201336.","journal-title":"J Clin Invest"},{"key":"7463_CR60","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1161\/CIRCULATIONAHA.120.046789","volume":"142","author":"N Xia","year":"2020","unstructured":"Xia N, Lu Y, Gu M, et al. A unique population of regulatory T cells in heart potentiates cardiac protection from myocardial infarction. Circulation. 2020;142:1956\u201373.","journal-title":"Circulation"},{"key":"7463_CR61","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/iub.2364","volume":"72","author":"H Hu","year":"2020","unstructured":"Hu H, Wu J, Cao C, et al. Exosomes derived from regulatory T cells ameliorate acute myocardial infarction by promoting macrophage M2 polarization. IUBMB Life. 2020;72:2409\u201319.","journal-title":"IUBMB Life"},{"key":"7463_CR62","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.7150\/thno.32734","volume":"9","author":"J Li","year":"2019","unstructured":"Li J, Yang KY, Tam RCY, et al. Regulatory T-cells regulate neonatal heart regeneration by potentiating cardiomyocyte proliferation in a paracrine manner. Theranostics. 2019;9:4324\u201341.","journal-title":"Theranostics"},{"key":"7463_CR63","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/s41467-018-04908-z","volume":"9","author":"S Zacchigna","year":"2018","unstructured":"Zacchigna S, Martinelli V, Moimas S, et al. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction. Nat Commun. 2018;9:2432.","journal-title":"Nat Commun"},{"key":"7463_CR64","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2353\/ajpath.2010.090759","volume":"176","author":"M Dobaczewski","year":"2010","unstructured":"Dobaczewski M, Xia Y, Bujak M, et al. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol. 2010;176:2177\u201387.","journal-title":"Am J Pathol"},{"key":"7463_CR65","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1161\/CIRCULATIONAHA.118.036053","volume":"139","author":"Y Wang","year":"2019","unstructured":"Wang Y, Dembowsky K, Chevalier E, et al. C-X-C motif chemokine receptor 4 blockade promotes tissue repair after myocardial infarction by enhancing regulatory T Cell mobilization and immune-regulatory function. Circulation. 2019;139:1798\u2013812.","journal-title":"Circulation"},{"key":"7463_CR66","doi-asserted-by":"crossref","unstructured":"Zhu R, Sun H, Yu K, et al. Interleukin-37 and dendritic cells treated with interleukin-37 plus troponin I ameliorate cardiac remodeling after myocardial infarction. J Am Heart Assoc.\u00a02016; 5(12):e004406.","DOI":"10.1161\/JAHA.116.004406"},{"key":"7463_CR67","doi-asserted-by":"publisher","first-page":"9515346","DOI":"10.1155\/2019\/9515346","volume":"2019","author":"X Mao","year":"2019","unstructured":"Mao X, Zhu R, Zhang F, et al. IL-37 Plays a beneficial role in patients with acute coronary syndrome. Mediators Inflamm. 2019;2019:9515346.","journal-title":"Mediators Inflamm"},{"key":"7463_CR68","doi-asserted-by":"crossref","unstructured":"Abbas AK, Trotta E, D RS, et al. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol.\u00a02018;3(25):eaat1482.","DOI":"10.1126\/sciimmunol.aat1482"},{"key":"7463_CR69","doi-asserted-by":"publisher","first-page":"8493767","DOI":"10.1155\/2016\/8493767","volume":"2016","author":"Z Zeng","year":"2016","unstructured":"Zeng Z, Yu K, Chen L, et al. Interleukin-2\/anti-interleukin-2 immune complex attenuates cardiac remodeling after myocardial infarction through expansion of regulatory T cells. J Immunol Res. 2016;2016:8493767.","journal-title":"J Immunol Res"},{"key":"7463_CR70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.hfc.2019.02.003","volume":"15","author":"S Paolillo","year":"2019","unstructured":"Paolillo S, Marsico F, Prastaro M, et al. Diabetic cardiomyopathy: definition, diagnosis, and therapeutic implications. Heart Fail Clin. 2019;15:341\u20137.","journal-title":"Heart Fail Clin"},{"key":"7463_CR71","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1155\/2013\/931915","volume":"35","author":"F Mahmoud","year":"2013","unstructured":"Mahmoud F. Al-Ozairi E Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes. Dis Markers. 2013;35:235\u201341.","journal-title":"Dis Markers"},{"key":"7463_CR72","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1253\/circj.CJ-19-1182","volume":"84","author":"Y Han","year":"2020","unstructured":"Han Y, Lai J, Tao J, et al. Sustaining circulating regulatory T cell subset contributes to the therapeutic effect of paroxetine on mice with diabetic cardiomyopathy. Circ J. 2020;84:1587\u201398.","journal-title":"Circ J"},{"key":"7463_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jad.2009.10.018","volume":"124","author":"Y Li","year":"2010","unstructured":"Li Y, Xiao B, Qiu W, et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. J Affect Disord. 2010;124:68\u201375.","journal-title":"J Affect Disord"},{"key":"7463_CR74","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2019.03.017","volume":"114","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang H, Wang Z, et al. 5-Hydroxytryptamine1a receptors on tumour cells induce immune evasion in lung adenocarcinoma patients with depression via autophagy\/pSTAT3. Eur J Cancer. 2019;114:8\u201324.","journal-title":"Eur J Cancer"},{"key":"7463_CR75","doi-asserted-by":"publisher","first-page":"5512322","DOI":"10.1155\/2021\/5512322","volume":"2021","author":"J Tao","year":"2021","unstructured":"Tao J, Chen H, Wang YJ, et al. Ketogenic diet suppressed T-regulatory cells and promoted cardiac fibrosis via reducing mitochondria-associated membranes and inhibiting mitochondrial function. Oxid Med Cell Longev. 2021;2021:5512322.","journal-title":"Oxid Med Cell Longev"},{"key":"7463_CR76","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/ATVBAHA.120.314211","volume":"41","author":"RP Choudhury","year":"2021","unstructured":"Choudhury RP, Edgar L, Ryd\u00e9n M, et al. Diabetes and metabolic drivers of trained immunity: new therapeutic targets beyond glucose. Arterioscler Thromb Vasc Biol. 2021;41:1284\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7463_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.18565\/cardio.2016.10.13-21","volume":"56","author":"AN Sumin","year":"2016","unstructured":"Sumin AN, Bezdenezhnyh NA, Bezdenezhnyh AV, et al. Factors associated with immediate results of coronary artery bypass grafting in patients with ischemic heart disease in the presence of type 2 diabetes. Kardiologiia. 2016;56:13\u201321.","journal-title":"Kardiologiia"},{"key":"7463_CR78","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.pcd.2012.02.002","volume":"6","author":"AH Heald","year":"2012","unstructured":"Heald AH, Knapman H, Nair S, et al. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile. Prim Care Diabetes. 2012;6:213\u20139.","journal-title":"Prim Care Diabetes"},{"key":"7463_CR79","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00125-009-1537-y","volume":"52","author":"A Remuzzi","year":"2009","unstructured":"Remuzzi A, Cornolti R, Bianchi R, et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia. 2009;52:2653\u201361.","journal-title":"Diabetologia"},{"key":"7463_CR80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diabet.2015.10.001","volume":"42","author":"S Faghihi-Kashani","year":"2016","unstructured":"Faghihi-Kashani S, Bonnet F, Hafezi-Nejad N, et al. Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. Diabetes Metab. 2016;42:55\u201361.","journal-title":"Diabetes Metab"},{"key":"7463_CR81","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s001250051556","volume":"43","author":"E Standl","year":"2000","unstructured":"Standl E. Schnell O A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia. 2000;43:1455\u201369.","journal-title":"Diabetologia"},{"key":"7463_CR82","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1007\/s00125-007-0797-7","volume":"50","author":"CT Prince","year":"2007","unstructured":"Prince CT, Becker DJ, Costacou T, et al. Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia. 2007;50:2280\u20138.","journal-title":"Diabetologia"},{"key":"7463_CR83","doi-asserted-by":"publisher","first-page":"309","DOI":"10.17305\/bjbms.2008.2882","volume":"8","author":"B Asci\u0107-Buturovi\u0107","year":"2008","unstructured":"Asci\u0107-Buturovi\u0107 B. Kacila M Effects of basal insulin analog and metformin on glycaemia control and weight as risk factors for endothelial dysfunction. Bosn J Basic Med Sci. 2008;8:309\u201312.","journal-title":"Bosn J Basic Med Sci"},{"key":"7463_CR84","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1007\/s00125-010-1887-5","volume":"53","author":"S Zervou","year":"2010","unstructured":"Zervou S, Wang YF, Laiho A, et al. Short-term hyperglycaemia causes non-reversible changes in arterial gene expression in a fully \u2018switchable\u2019 in vivo mouse model of diabetes. Diabetologia. 2010;53:2676\u201387.","journal-title":"Diabetologia"},{"key":"7463_CR85","doi-asserted-by":"crossref","unstructured":"Lingvay I, Sumithran P, Cohen RV, et al. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet.\u00a02021;399(10322):394\u2013405.","DOI":"10.1016\/S0140-6736(21)01919-X"},{"key":"7463_CR86","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev-nutr-071816-064836","volume":"37","author":"JC Ralston","year":"2017","unstructured":"Ralston JC, Lyons CL, Kennedy EB, et al. Fatty acids and NLRP3 inflammasome-mediated inflammation in metabolic tissues. Annu Rev Nutr. 2017;37:77\u2013102.","journal-title":"Annu Rev Nutr"},{"key":"7463_CR87","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.1038\/s41598-018-26588-x","volume":"8","author":"A Uchinaka","year":"2018","unstructured":"Uchinaka A, Azuma N, Mizumoto H, et al. Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome. Sci Rep. 2018;8:8156.","journal-title":"Sci Rep"},{"key":"7463_CR88","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature06878","volume":"453","author":"L Zhou","year":"2008","unstructured":"Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453:236\u201340.","journal-title":"Nature"},{"key":"7463_CR89","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A. Kishimoto T IL-6: regulator of Treg\/Th17 balance. Eur J Immunol. 2010;40:1830\u20135.","journal-title":"Eur J Immunol"},{"key":"7463_CR90","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.numecd.2019.08.004","volume":"29","author":"SK Hong","year":"2019","unstructured":"Hong SK, Choo EH, Ihm SH, et al. High fat diet downregulates regulatory T cells in the myocardium of spontaneous hypertensive rats. Nutr Metab Cardiovasc Dis. 2019;29:1254\u201360.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"7463_CR91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cellimm.2014.02.003","volume":"288","author":"B Wang","year":"2014","unstructured":"Wang B, Sun J, Ma Y, et al. Increased oxidative stress and the apoptosis of regulatory T cells in obese mice but not resistant mice in response to a high-fat diet. Cell Immunol. 2014;288:39\u201346.","journal-title":"Cell Immunol"},{"key":"7463_CR92","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nrcardio.2015.108","volume":"12","author":"A Pollack","year":"2015","unstructured":"Pollack A, Kontorovich AR, Fuster V, et al. Viral myocarditis\u2013diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12:670\u201380.","journal-title":"Nat Rev Cardiol"},{"key":"7463_CR93","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(11)60648-X","volume":"379","author":"S Sagar","year":"2012","unstructured":"Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. 2012;379:738\u201347.","journal-title":"Lancet"},{"key":"7463_CR94","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrcardio.2015.169","volume":"13","author":"X Meng","year":"2016","unstructured":"Meng X, Yang J, Dong M, et al. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol. 2016;13:167\u201379.","journal-title":"Nat Rev Cardiol"},{"key":"7463_CR95","doi-asserted-by":"publisher","first-page":"e74955","DOI":"10.1371\/journal.pone.0074955","volume":"8","author":"Y Cao","year":"2013","unstructured":"Cao Y, Xu W. Xiong S Adoptive transfer of regulatory T cells protects against Coxsackievirus B3-induced cardiac fibrosis. PLoS ONE. 2013;8:e74955.","journal-title":"PLoS ONE"},{"key":"7463_CR96","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1161\/CIRCULATIONAHA.109.893248","volume":"121","author":"Y Shi","year":"2010","unstructured":"Shi Y, Fukuoka M, Li G, et al. Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation. 2010;121:2624\u201334.","journal-title":"Circulation"},{"key":"7463_CR97","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaut.2011.01.006","volume":"36","author":"G Fousteri","year":"2011","unstructured":"Fousteri G, Dave A, Morin B, et al. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun. 2011;36:210\u201320.","journal-title":"J Autoimmun"},{"key":"7463_CR98","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.lfs.2014.01.007","volume":"118","author":"K Tajiri","year":"2014","unstructured":"Tajiri K, Sakai S, Kimura T, et al. Endothelin receptor antagonist exacerbates autoimmune myocarditis in mice. Life Sci. 2014;118:288\u201396.","journal-title":"Life Sci"},{"key":"7463_CR99","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/cvr\/cvs077","volume":"94","author":"AP Papageorgiou","year":"2012","unstructured":"Papageorgiou AP, Swinnen M, Vanhoutte D, et al. Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res. 2012;94:115\u201324.","journal-title":"Cardiovasc Res"},{"key":"7463_CR100","doi-asserted-by":"publisher","first-page":"e12477","DOI":"10.1111\/1755-5922.12477","volume":"36","author":"K Dai","year":"2018","unstructured":"Dai K, Wang Y, Tai S, et al. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis. Cardiovasc Ther. 2018;36:e12477.","journal-title":"Cardiovasc Ther"},{"key":"7463_CR101","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1080\/21505594.2018.1482179","volume":"9","author":"Z De-Pu","year":"2018","unstructured":"De-Pu Z, Li-Sha G, Guang-Yi C, et al. The cholinergic anti-inflammatory pathway ameliorates acute viral myocarditis in mice by regulating CD4(+) T cell differentiation. Virulence. 2018;9:1364\u201376.","journal-title":"Virulence"},{"key":"7463_CR102","doi-asserted-by":"crossref","unstructured":"Pappritz K, Savvatis K, Miteva K, et al. Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. Faseb J.\u00a02018;4:fj201701408R.","DOI":"10.1096\/fj.201701408R"},{"key":"7463_CR103","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1161\/CIRCRESAHA.109.195230","volume":"105","author":"K Li","year":"2009","unstructured":"Li K, Xu W, Guo Q, et al. Differential macrophage polarization in male and female BALB\/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res. 2009;105:353\u201364.","journal-title":"Circ Res"},{"key":"7463_CR104","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/cvr\/cvt246","volume":"101","author":"JH Lee","year":"2014","unstructured":"Lee JH, Kim TH, Park HE, et al. Myosin-primed tolerogenic dendritic cells ameliorate experimental autoimmune myocarditis. Cardiovasc Res. 2014;101:203\u201310.","journal-title":"Cardiovasc Res"},{"key":"7463_CR105","doi-asserted-by":"publisher","first-page":"104269","DOI":"10.1016\/j.phrs.2019.104269","volume":"146","author":"J Wu","year":"2019","unstructured":"Wu J, Liu M, Mang G, et al. Protosappanin A protects against experimental autoimmune myocarditis, and induces metabolically reprogrammed tolerogenic DCs. Pharmacol Res. 2019;146:104269.","journal-title":"Pharmacol Res"},{"key":"7463_CR106","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(04)16358-7","volume":"363","author":"P Elliott","year":"2004","unstructured":"Elliott P. McKenna WJ Hypertrophic cardiomyopathy. Lancet. 2004;363:1881\u201391.","journal-title":"Lancet"},{"key":"7463_CR107","first-page":"344","volume":"16","author":"S Yakar T\u00fcl\u00fcce","year":"2016","unstructured":"Yakar T\u00fcl\u00fcce S, T\u00fcl\u00fcce K, \u00c7il Z, et al. Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatol J Cardiol. 2016;16:344\u20138.","journal-title":"Anatol J Cardiol"},{"key":"7463_CR108","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/heartjnl-2011-300960","volume":"98","author":"J Kuusisto","year":"2012","unstructured":"Kuusisto J, K\u00e4rj\u00e4 V, Sipola P, et al. Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy. Heart. 2012;98:1007\u201313.","journal-title":"Heart"},{"key":"7463_CR109","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1136\/heartjnl-2012-301730","volume":"98","author":"D Westermann","year":"2012","unstructured":"Westermann D. Does inflammation trigger fibrosis in hypertrophic cardiomyopathy: a burning question? Heart. 2012;98:965\u20136.","journal-title":"Heart"},{"key":"7463_CR110","doi-asserted-by":"publisher","first-page":"696321","DOI":"10.3389\/fcvm.2021.696321","volume":"8","author":"XZ Zhang","year":"2021","unstructured":"Zhang XZ, Zhang S, Tang TT, et al. Bioinformatics and immune infiltration analyses reveal the key pathway and immune cells in the pathogenesis of hypertrophic cardiomyopathy. Front Cardiovasc Med. 2021;8:696321.","journal-title":"Front Cardiovasc Med"},{"key":"7463_CR111","first-page":"5063","volume":"9","author":"L Fang","year":"2017","unstructured":"Fang L, Ellims AH, Beale AL, et al. Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res. 2017;9:5063\u201373.","journal-title":"Am J Transl Res"},{"key":"7463_CR112","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT. Reuser AJ Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"7463_CR113","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.4161\/hv.21405","volume":"8","author":"LP Cousens","year":"2012","unstructured":"Cousens LP, Mingozzi F, van der Marel S, et al. Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother. 2012;8:1459\u201364.","journal-title":"Hum Vaccin Immunother"},{"key":"7463_CR114","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/mt.2009.195","volume":"18","author":"B Sun","year":"2010","unstructured":"Sun B, Kulis MD, Young SP, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther. 2010;18:353\u201360.","journal-title":"Mol Ther"},{"key":"7463_CR115","first-page":"Cd001919","volume":"11","author":"TF Crocker","year":"2021","unstructured":"Crocker TF, Brown L, Lam N, et al. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021;11:Cd001919.","journal-title":"Cochrane Database Syst Rev"},{"key":"7463_CR116","doi-asserted-by":"crossref","unstructured":"Puzzo F, Colella P, Biferi MG, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase. Sci Transl Med.\u00a02017;9(418):eaam6375.","DOI":"10.1126\/scitranslmed.aam6375"},{"key":"7463_CR117","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1042\/CS20160043","volume":"130","author":"V Austin","year":"2016","unstructured":"Austin V, Crack PJ, Bozinovski S, et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016;130:1039\u201350.","journal-title":"Clin Sci (Lond)"},{"key":"7463_CR118","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.biopha.2018.09.113","volume":"108","author":"X Zheng","year":"2018","unstructured":"Zheng X, Zhang L, Chen J, et al. Dendritic cells and Th17\/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease. Biomed Pharmacother. 2018;108:1141\u201351.","journal-title":"Biomed Pharmacother"},{"key":"7463_CR119","doi-asserted-by":"publisher","first-page":"15625","DOI":"10.1073\/pnas.1906303116","volume":"116","author":"S Bruzzaniti","year":"2019","unstructured":"Bruzzaniti S, Bocchino M, Santopaolo M, et al. An immunometabolic pathomechanism for chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2019;116:15625\u201334.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7463_CR120","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1183\/09031936.00010407","volume":"31","author":"B Barcel\u00f3","year":"2008","unstructured":"Barcel\u00f3 B, Pons J, Ferrer JM, et al. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J. 2008;31:555\u201362.","journal-title":"Eur Respir J"},{"key":"7463_CR121","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3389\/fimmu.2020.00723","volume":"11","author":"J Hou","year":"2020","unstructured":"Hou J. Sun Y Role of Regulatory T cells in disturbed immune homeostasis in patients with chronic obstructive pulmonary disease. Front Immunol. 2020;11:723.","journal-title":"Front Immunol"},{"key":"7463_CR122","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1080\/08923973.2016.1188402","volume":"38","author":"S Imani","year":"2016","unstructured":"Imani S, Salimian J, Fu J, et al. Th17\/Treg-related cytokine imbalance in sulfur mustard exposed and stable chronic obstructive pulmonary (COPD) patients: correlation with disease activity. Immunopharmacol Immunotoxicol. 2016;38:270\u201380.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"7463_CR123","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.envpol.2017.03.070","volume":"226","author":"XY Gu","year":"2017","unstructured":"Gu XY, Chu X, Zeng XL, et al. Effects of PM2.5 exposure on the Notch signaling pathway and immune imbalance in chronic obstructive pulmonary disease. Environ Pollut. 2017;226:163\u201373.","journal-title":"Environ Pollut"},{"key":"7463_CR124","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM. Borlaug BA Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124:1598\u2013617.","journal-title":"Circ Res"},{"key":"7463_CR125","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra S. Kass DA Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18:400\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"119","key":"7463_CR126","first-page":"1233","volume":"2015","author":"FR Heinzel","year":"1985","unstructured":"Heinzel FR, Hohendanner F, Jin G, et al. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol. 1985;2015(119):1233\u201342.","journal-title":"J Appl Physiol"},{"key":"7463_CR127","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.cca.2010.08.013","volume":"411","author":"N Li","year":"2010","unstructured":"Li N, Bian H, Zhang J, et al. The Th17\/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clin Chim Acta. 2010;411:1963\u20138.","journal-title":"Clin Chim Acta"},{"key":"7463_CR128","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2147\/JIR.S331320","volume":"14","author":"S Liao","year":"2021","unstructured":"Liao S, Tang Y, Yue X, et al. \u03b2-Hydroxybutyrate mitigated heart failure with preserved ejection fraction by increasing treg cells via Nox2\/GSK-3\u03b2. J Inflamm Res. 2021;14:4697\u2013706.","journal-title":"J Inflamm Res"},{"key":"7463_CR129","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4049\/jimmunol.0900691","volume":"183","author":"WE O'Gorman","year":"2009","unstructured":"O\u2019Gorman WE, Dooms H, Thorne SH, et al. The initial phase of an immune response functions to activate regulatory T cells. J Immunol. 2009;183:332\u20139.","journal-title":"J Immunol"},{"key":"7463_CR130","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1161\/HYPERTENSIONAHA.116.07084","volume":"68","author":"H Wang","year":"2016","unstructured":"Wang H, Hou L, Kwak D, et al. Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression. Hypertension. 2016;68:114\u201322.","journal-title":"Hypertension"},{"key":"7463_CR131","doi-asserted-by":"crossref","unstructured":"Katsuki M, Hirooka Y, Kishi T et al. Decreased proportion of Foxp3+ CD4+ regulatory T cells contributes to the development of hypertension in genetically hypertensive rats. J Hypertens. 2015;33:773\u2013783; discussion 783","DOI":"10.1097\/HJH.0000000000000469"},{"key":"7463_CR132","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","volume":"50","author":"JB Wing","year":"2019","unstructured":"Wing JB, Tanaka A. Sakaguchi S Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50:302\u201316.","journal-title":"Immunity"},{"key":"7463_CR133","doi-asserted-by":"publisher","first-page":"83ra41","DOI":"10.1126\/scitranslmed.3001809","volume":"3","author":"KL Hippen","year":"2011","unstructured":"Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3:83ra41.","journal-title":"Sci Transl Med"},{"key":"7463_CR134","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein CG, Miller JS, McKenna DH, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood. 2016;127:1044\u201351.","journal-title":"Blood"},{"key":"7463_CR135","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015;7:315ra189.","journal-title":"Sci Transl Med"},{"key":"7463_CR136","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT. Bluestone JA T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20:158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"7463_CR137","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3389\/fimmu.2020.01608","volume":"11","author":"YR Mohseni","year":"2020","unstructured":"Mohseni YR, Tung SL, Dudreuilh C, et al. The future of regulatory T cell therapy: promises and challenges of implementing CAR technology. Front Immunol. 2020;11:1608.","journal-title":"Front Immunol"},{"key":"7463_CR138","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","volume":"18","author":"LMR Ferreira","year":"2019","unstructured":"Ferreira LMR, Muller YD, Bluestone JA, et al. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019;18:749\u201369.","journal-title":"Nat Rev Drug Discov"},{"key":"7463_CR139","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2004-01-0086","volume":"104","author":"P Hoffmann","year":"2004","unstructured":"Hoffmann P, Eder R, Kunz-Schughart LA, et al. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood. 2004;104:895\u2013903.","journal-title":"Blood"},{"key":"7463_CR140","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2006-06-027409","volume":"108","author":"P Hoffmann","year":"2006","unstructured":"Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006;108:4260\u20137.","journal-title":"Blood"},{"key":"7463_CR141","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2013-03-489443","volume":"122","author":"JH Peters","year":"2013","unstructured":"Peters JH, Koenen HJ, Fasse E, et al. Human secondary lymphoid organs typically contain polyclonally-activated proliferating regulatory T cells. Blood. 2013;122:2213\u201323.","journal-title":"Blood"},{"key":"7463_CR142","doi-asserted-by":"publisher","first-page":"304ps318","DOI":"10.1126\/scitranslmed.aaa7721","volume":"7","author":"P Trzonkowski","year":"2015","unstructured":"Trzonkowski P, Bacchetta R, Battaglia M, et al. Hurdles in therapy with regulatory T cells. Sci Transl Med. 2015;7:304ps318.","journal-title":"Sci Transl Med"},{"key":"7463_CR143","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.7150\/thno.47118","volume":"10","author":"THW Fung","year":"2020","unstructured":"Fung THW, Yang KY. Lui KO An emerging role of regulatory T-cells in cardiovascular repair and regeneration. Theranostics. 2020;10:8924\u201338.","journal-title":"Theranostics"},{"key":"7463_CR144","doi-asserted-by":"publisher","first-page":"e022452","DOI":"10.1136\/bmjopen-2018-022452","volume":"8","author":"TX Zhao","year":"2018","unstructured":"Zhao TX, Kostapanos M, Griffiths C, et al. Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I\/II clinical trial. BMJ Open. 2018;8:e022452.","journal-title":"BMJ Open"},{"key":"7463_CR145","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-981-15-1671-9_13","volume":"1229","author":"J He","year":"2020","unstructured":"He J, Luo Y, Song J, et al. Non-coding RNAs and pathological cardiac hypertrophy. Adv Exp Med Biol. 2020;1229:231\u201345.","journal-title":"Adv Exp Med Biol"},{"key":"7463_CR146","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1161\/HYPERTENSIONAHA.120.14752","volume":"76","author":"PL Li","year":"2020","unstructured":"Li PL, Liu H, Chen GP, et al. STEAP3 (six-transmembrane epithelial antigen of prostate 3) inhibits pathological cardiac hypertrophy. Hypertension. 2020;76:1219\u201330.","journal-title":"Hypertension"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07463-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:05:17Z","timestamp":1727496317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07463-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":146,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7463"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07463-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"29 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}